Atlas Trials

Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer

Clinical trial NCT05119296 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05119296
Sponsor
Stanford University
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Thyroid Cancer
Start date
2022-02-15
Primary completion
2025-05-16
Enrollment
12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.